Billiontoone (NASDAQ:BLLN) CTO Sells $2,045,400.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00. Following the transaction, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $102,270. This represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

Shares of BLLN stock opened at $105.15 on Friday. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The firm has a market capitalization of $4.84 billion and a price-to-earnings ratio of 191.18. The business has a 50 day simple moving average of $89.82 and a 200 day simple moving average of $87.35.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. During the same period in the previous year, the firm earned ($0.39) EPS. The firm’s revenue was up 83.8% on a year-over-year basis. On average, equities research analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Trading of Billiontoone

Hedge funds and other institutional investors have recently modified their holdings of the company. Adams Street Partners LLC bought a new position in Billiontoone during the fourth quarter valued at about $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone during the fourth quarter worth about $103,786,000. Price T Rowe Associates Inc. MD bought a new stake in Billiontoone in the fourth quarter worth about $39,717,000. JPMorgan Chase & Co. bought a new stake in Billiontoone in the fourth quarter worth about $32,078,000. Finally, Wasatch Advisors LP acquired a new stake in Billiontoone in the 1st quarter valued at about $29,179,000.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BLLN shares. JPMorgan Chase & Co. lifted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Guggenheim boosted their price target on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. BTIG Research reduced their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Billiontoone currently has a consensus rating of “Moderate Buy” and an average target price of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.